Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Managing risk of pregnancy
The teratogenicity of isotretinoin has been known since isotretinoin was first introduced for acne treatment. Because of this, Patricia Farris, M.D., a dermatologist based in Metairie, La., not only insists on adequate birth control use but adds that the patient must be open to the possibility that if her birth control fails that she would terminate the pregnancy.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
